Insiders who reported open-market trades in the last 12 months at the companies Patricia A. Bradford files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Robert J. Bitterman - $45K in PHIO purchases and sales in the last 12 months
Ronald Todd Plott - $27K in PHIO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Patricia A. Bradford is a corporate insider, tracked as Director of Phio Pharmaceuticals Corp. (PHIO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Patricia A. Bradford submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Patricia A. Bradford been buying or selling stock?
Recorded transactions: 2 open-market purchases ($19K) and 0 open-market sales across all tracked filings.
Patricia A. Bradford is Director of Phio Pharmaceuticals Corp. (PHIO). 4 SEC Form 4 filings on record going back to 2025, most recently on 25 September 2026. Most recent open-market trade: bought $7K of PHIO on 25 September 2026. Lifetime open-market purchases: $19K.
Recent transactions
4
The latest 4 SEC Form 4 transactions reported by Patricia A. Bradford.
InsiderAlpha's records for Patricia A. Bradford go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. The typical open-market purchase is $9K (2 buys totaling $19K). The largest single buy on record is $12K of PHIO in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
